Anuj Verma, MBBS, MD
DownloadHi-Res Photo
About
Titles
Clinical Fellow
Biography
I completed my Medical school in GMC Kolhapur, India followed by residency in Pathology at Tata Memorial Hospital, Mumbai, India. I was a postdoctoral fellow in the Dept. of Translational Molecular Pathology at MD Anderson, Cancer Center, Houston. My area of interest is Hematopathology.
Appointments
Education & Training
- PostDoctoral Fellow
- MD Anderson Cancer Center (2020)
- MD
- Tata Memorial Hospital, Pathology (2014)
- MBBS
- GMC Kolhapur (2010)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Anuj Verma's published research.
Publications Timeline
A big-picture view of Anuj Verma's research output by year.
Cristina A. Figueroa Villalba, MD
Joe El-Khoury, PhD, DABCC, FACB
9Publications
66Citations
Publications
2024
New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis
Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Solis Soto L, Jadhav A, Wistuba I, Menter D, Kopetz S, Parra E, Vauthey J, Maru D. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Reports 2024, 2: 37. DOI: 10.1038/s44276-024-00056-8.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesRecurrence-free survivalCancer liver metastasesTumor-associated macrophagesT cell subtypesPreoperative chemotherapyLiver metastasesT cellsColorectal cancer liver metastases patientsM2 macrophagesAssociated with shorter recurrence-free survivalShorter recurrence-free survivalPredictor of favorable prognosisRegulatory T cellsMacrophage polarizationCytotoxic T cellsHelper T cellsDensity of M2 macrophagesCause of mortalityFavorable prognosisPrognostic roleM2 macrophage polarizationTumor biologyTumor samplesColorectal cancerAtezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study
de Sousa L, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas E, Cho W, Wistuba I, Yao J, Woodman S, Halperin D, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncology 2024, 151: 106747. PMID: 38460288, DOI: 10.1016/j.oraloncology.2024.106747.Peer-Reviewed Original ResearchAltmetric
2022
A case of spuriously low serum creatinine concentrations in a patient with acetaminophen poisoning
Verma A, Figueroa Villalba C, Choucair I, El-Khoury JM. A case of spuriously low serum creatinine concentrations in a patient with acetaminophen poisoning. Clinica Chimica Acta 2022, 535: 195-196. PMID: 36075459, DOI: 10.1016/j.cca.2022.09.001.Peer-Reviewed Original ResearchCitationsPhase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baselineEmerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsy
2021
An analysis of research biopsy core variability from over 5000 prospectively collected core samples
Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba I, Gupta S, Lee J, Overman M, Tam A. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. Npj Precision Oncology 2021, 5: 94. PMID: 34707215, PMCID: PMC8551285, DOI: 10.1038/s41698-021-00234-8.Peer-Reviewed Original ResearchCitationsAltmetricARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Sarshekeh A, Alshenaifi J, Roszik J, Manyam G, Advani S, Katkhuda R, Verma A, Lam M, Willis J, Shen J, Morris J, Davis J, Loree J, Lee H, Ajani J, Maru D, Overman M, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research 2021, 27: 1663-1670. PMID: 33414133, PMCID: PMC7956157, DOI: 10.1158/1078-0432.ccr-20-2404.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMicrosatellite stable colorectal cancerColorectal cancerStable colorectal cancerMutant casesCancer Center databaseT-cell markersTumor mutational burdenAT-rich interactive domain 1AUnique molecular subgroupSignificant higher expressionCancer Genome AtlasImmunologic featuresIFNγ expressionImmune activationImmune subtypesTreatment strategiesPreclinical modelsT cellsImmune responseMutational burdenSeparate cohortPatientsTherapy trialsActive subgroupMolecular subgroups
2020
Chagas disease initially diagnosed in a lymph node.
Verma A, Pan Z. Chagas disease initially diagnosed in a lymph node. Blood 2020, 136: 2478. PMID: 33211840, DOI: 10.1182/blood.2020008815.Peer-Reviewed Original Research
2019
Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.
Mehrvarz Sarshekeh A, Katkhuda R, Verma A, Advani S, Overman M, Maru D, Kopetz S. Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer. Journal Of Clinical Oncology 2019, 37: 3577-3577. DOI: 10.1200/jco.2019.37.15_suppl.3577.Peer-Reviewed Original ResearchConceptsConsensus molecular subtype 4Colorectal cancerMSS colorectal cancerEMT gene signatureCTL infiltrationIntratumoral infiltrationImmune cellsTumor microenvironmentGene signatureMicrosatellite stable colorectal cancerAssociation of TGFInfiltration of CTLsHigh relapse rateRank correlation analysisCytotoxic T lymphocytesTGF-β expressionTGF-β activationExpression levelsTGF-β pathwayParaffin-embedded samplesRelapse rateImmunotherapy responseMacrophage infiltrationPoor prognosisTumor infiltration
Get In Touch
Contacts
Email